Investors Focus On Devices, Services In China, But Drug R&D Still Has Some Attraction
This article was originally published in PharmAsia News
Executive Summary
China attracted $1.9 billion in private equity investment in health care-related fields in 2013, making the sector second only to real estate. But investors at a recent forum in Beijing had divergent opinions on whether the smart money should head into developing devices, clinics or new drug R&D.
You may also be interested in...
Chinese Language Podcast: ASCO专集
J&J and Legend’s Carvykti shines at ASCO while Junshi provides PD-1 antibody toripalimab updates. Alongside, ADCs from Biokin, BlissBio also steps into the spotlight. Guest speaker Leon Tang in the US, Brian Yang in Beijing and Dexter Yan in Shanghai discuss what stands out in this special ASCO episode of the latest Chinese-language podcast.
China Further Tightens Oversight Of Human Genetic Research
Although the latest implementing details classify many aspects of human genetic resource handling and transfer, foreign entities are severely restricted from developing gene and gene-editing therapies in China. Legal experts say the changes combined with data transfer and recent cybersecurity legislation pose additional challenges to life science companies operating in the country.
Falling At The Start Line: Chinese Firms Face Multiple Commercial Challenges Beyond Price, Coverage
Sales of a global first-in-class dermatology drug that gained its first approval in China are falling well behind those of its overseas counterpart. Brian Yang takes a deeper look into the multiple underlying factors determining success in the world's second-largest pharma market beyond pricing and reimbursement coverage, including complex hospital entry, dual channels and competition considerations.